中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
10期
897-900
,共4页
王瑾%高磊%邱慧颖%章卫平%杨建民%宋献民%吕书晴%陈洁%王健民
王瑾%高磊%邱慧穎%章衛平%楊建民%宋獻民%呂書晴%陳潔%王健民
왕근%고뢰%구혜영%장위평%양건민%송헌민%려서청%진길%왕건민
淋巴瘤,T细胞,外周%抗肿瘤联合化疗方案%疗效比较研究%安全
淋巴瘤,T細胞,外週%抗腫瘤聯閤化療方案%療效比較研究%安全
림파류,T세포,외주%항종류연합화료방안%료효비교연구%안전
Lymphoma,T-cell,peripheral%Antineoplastic combined chemotherapy protocols%Comparative effectiveness research%Safety
目的 比较Hyper CVAD(大剂量环磷酰胺、表阿霉素、长春地辛、地塞米松)/MA(大剂量甲氨蝶呤、阿糖胞苷)方案与CHOP(环磷酰胺、阿霉素、长春新碱、泼尼松)/CHOP样方案治疗初发外周T细胞淋巴瘤(PTCL)患者的疗效与安全性.方法 回顾性分析80例初发PTCL患者资料,并对接受Hyper CVAD/MA与CHOP/CHOP样方案患者的疗效及不良反应进行比较.结果 80例患者中23例接受Hyper CVAD/MA方案化疗(HM组),57例接受CHOP/CHOP样方案化疗(CC组).HM组与CC组患者的总有效率(ORR)(78.3%对54.4%,P=0.047)、IPI评分≤2分患者的ORR率(86.7%对55.2%,P=0.037)、获得缓解所需的化疗疗程数(4个对6个,P=0.004)、中位无进展生存(PFS)时间(24个月对12个月,P=0.039)及1年PFS率(82.6%对45.6%,P=0.006)差异均有统计学意义;而两组患者的复发率相似(50.0%对54.8%,P=0.744),2年、3年PFS率和3年总生存率差异均无统计学意义(P值均>0.05).HM组患者较CC组患者更易发生中性粒细胞减少(<1.5× 10 9/L者的比例分别为73.9%和38.6%,P=0.004).结论 Hyper CVAD/MA方案作为诱导方案治疗除ALK阳性外的PTCL患者的近期疗效优于CHOP/CHOP样方案.
目的 比較Hyper CVAD(大劑量環燐酰胺、錶阿黴素、長春地辛、地塞米鬆)/MA(大劑量甲氨蝶呤、阿糖胞苷)方案與CHOP(環燐酰胺、阿黴素、長春新堿、潑尼鬆)/CHOP樣方案治療初髮外週T細胞淋巴瘤(PTCL)患者的療效與安全性.方法 迴顧性分析80例初髮PTCL患者資料,併對接受Hyper CVAD/MA與CHOP/CHOP樣方案患者的療效及不良反應進行比較.結果 80例患者中23例接受Hyper CVAD/MA方案化療(HM組),57例接受CHOP/CHOP樣方案化療(CC組).HM組與CC組患者的總有效率(ORR)(78.3%對54.4%,P=0.047)、IPI評分≤2分患者的ORR率(86.7%對55.2%,P=0.037)、穫得緩解所需的化療療程數(4箇對6箇,P=0.004)、中位無進展生存(PFS)時間(24箇月對12箇月,P=0.039)及1年PFS率(82.6%對45.6%,P=0.006)差異均有統計學意義;而兩組患者的複髮率相似(50.0%對54.8%,P=0.744),2年、3年PFS率和3年總生存率差異均無統計學意義(P值均>0.05).HM組患者較CC組患者更易髮生中性粒細胞減少(<1.5× 10 9/L者的比例分彆為73.9%和38.6%,P=0.004).結論 Hyper CVAD/MA方案作為誘導方案治療除ALK暘性外的PTCL患者的近期療效優于CHOP/CHOP樣方案.
목적 비교Hyper CVAD(대제량배린선알、표아매소、장춘지신、지새미송)/MA(대제량갑안접령、아당포감)방안여CHOP(배린선알、아매소、장춘신감、발니송)/CHOP양방안치료초발외주T세포림파류(PTCL)환자적료효여안전성.방법 회고성분석80례초발PTCL환자자료,병대접수Hyper CVAD/MA여CHOP/CHOP양방안환자적료효급불량반응진행비교.결과 80례환자중23례접수Hyper CVAD/MA방안화료(HM조),57례접수CHOP/CHOP양방안화료(CC조).HM조여CC조환자적총유효솔(ORR)(78.3%대54.4%,P=0.047)、IPI평분≤2분환자적ORR솔(86.7%대55.2%,P=0.037)、획득완해소수적화료료정수(4개대6개,P=0.004)、중위무진전생존(PFS)시간(24개월대12개월,P=0.039)급1년PFS솔(82.6%대45.6%,P=0.006)차이균유통계학의의;이량조환자적복발솔상사(50.0%대54.8%,P=0.744),2년、3년PFS솔화3년총생존솔차이균무통계학의의(P치균>0.05).HM조환자교CC조환자경역발생중성립세포감소(<1.5× 10 9/L자적비례분별위73.9%화38.6%,P=0.004).결론 Hyper CVAD/MA방안작위유도방안치료제ALK양성외적PTCL환자적근기료효우우CHOP/CHOP양방안.
Objective To evaluate the curative efficacy and safety of two regimens,Hyper CVAD/ MA and CHOP/CHOP,in the treatment of primary peripheral T cell lymphoma (PTCL).Methods The clinical data of 80 primary PTCL patients were retrospectively analyzed,and the efficacy and safety of the two regimens,Hyper CVAD/MA and CHOP/CHOP,were evaluated.Results Of 80 patients with primary PTCL,23 were treated with HyperCVAD/MA regimen (HM group,experimental group) and 57 with CHOP or CHOP-like regimen (CC group,control group).The differences between overall response rate (ORR) among HM group and CC group (78.3% vs 54.4%,P=0.047),ORR in patients with IPI score of 0-2 (86.7% vs 55.2%,P=0.037),courses of chemotherapy to achieve remission (4 vs 6,P=0.004),median progression-free survival (PFS) time (24 months vs 12 months,P=0.039) and 1-year PFS rate (82.6%against 45.6%,P=0.006) were statistically significant.The relapse rates were similar between 2 groups (50.0% vs 54.8%,P=0.744).The 2-year and 3-year progression-free survivals and 3 year overall survival were not significantly different (P>0.05).Patients in Hyper CVAD/MA group are more susceptible to neutropenia (<1.5× 109/L) (73.9% vs 38.6%,P=0.004).Conclusion The curative effect ofHyper CVAD/MA regimen as induction therapy in treatment of PTCL patients except ALK positive PTCL patients was better than that of CHOP/CHOP-like regimen.